A Refractory Livedoid Vasculopathy Accompanied by Methylene Tetrahydrofolate Reductase Gene Polymorphism Successfully Treated with Hyperbaric Oxygen Therapy | Canada Hyperbarics Skip to main content
Case Report Ann Dermatol 2023

A Refractory Livedoid Vasculopathy Accompanied by Methylene Tetrahydrofolate Reductase Gene Polymorphism Successfully Treated with Hyperbaric Oxygen Therapy

Lee S, Lee Y, Choi E — Ann Dermatol, 2023

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers reported on a case where hyperbaric oxygen therapy successfully treated a 63-year-old woman with severe livedoid vasculopathy that had not responded to other treatments.

What They Found

A 63-year-old female patient with refractory livedoid vasculopathy, also having an MTHFR gene polymorphism, received hyperbaric oxygen therapy at 2.0 absolute atmosphere for 120 minutes, three times a week. After 4 sessions, her painful ulcers began to heal, and after 13 sessions, the skin lesions were almost completely healed. During an eight-month follow-up, the ulcers did not recur, and her symptoms remained stable.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This study is a single case report, which means its findings may not apply to all patients with livedoid vasculopathy.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Case Report
Category Wound Care
Source Pubmed
PubMed ID 37853867
Year Published 2023
Journal Ann Dermatol

Cite This Study

Share

This study relates to Problem Wounds. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Wound Care

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: April 17, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology